W
William A. Freed-Pastor
Researcher at Massachusetts Institute of Technology
Publications - 29
Citations - 2846
William A. Freed-Pastor is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Medicine & Pancreatic cancer. The author has an hindex of 11, co-authored 19 publications receiving 2004 citations. Previous affiliations of William A. Freed-Pastor include Columbia University & Harvard University.
Papers
More filters
Journal ArticleDOI
Mutant p53: one name, many proteins
TL;DR: Mechanisms by which Mutant p53 exerts its cellular effects are reviewed, with a particular focus on the burgeoning mutant p53 transcriptome, and the biological and clinical consequences of mutant p 53 gain of function are discussed.
Journal ArticleDOI
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
William A. Freed-Pastor,Hideaki Mizuno,Xi Zhao,Anita Langerød,Sung Hwan Moon,Ruth Rodriguez-Barrueco,Anthony M. Barsotti,Agustin Chicas,Wencheng Li,Alla Polotskaia,Mina J. Bissell,Timothy F. Osborne,Bin Tian,Scott W. Lowe,Jose M. Silva,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Arnold J. Levine,Jill Bargonetti,Carol Prives +19 more
TL;DR: It is found that mutant p53 depletion is sufficient to phenotypically revert breast cancer cells to a more acinar-like morphology, which implicate the mevalonate pathway as a therapeutic target for tumors bearing mutations in p53.
Journal ArticleDOI
p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression
Sung-Hwan Moon,Chun-Hao Huang,Chun-Hao Huang,Chun-Hao Huang,Shauna L. Houlihan,Kausik Regunath,William A. Freed-Pastor,John P. Morris,Darjus F. Tschaharganeh,Edward R. Kastenhuber,Anthony M. Barsotti,Rachel Culp-Hill,Wen Xue,Yu-Jui Ho,Timour Baslan,Xiang Li,Xiang Li,Allison Mayle,Elisa de Stanchina,Lars Zender,David R. Tong,Angelo D'Alessandro,Scott W. Lowe,Carol Prives +23 more
TL;DR: It is demonstrated that repression of the mevalonate pathway is a crucial component of p53-mediated liver tumor suppression and the mechanism by which this occurs is outlined.
Journal ArticleDOI
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
Neil T. Pfister,Vitalay Fomin,Kausik Regunath,Jeffrey Y. Zhou,Wen Zhou,Laxmi Silwal-Pandit,Laxmi Silwal-Pandit,William A. Freed-Pastor,William A. Freed-Pastor,Oleg Laptenko,Suat Peng Neo,Jill Bargonetti,Mainul Hoque,Bin Tian,Jayantha Gunaratne,Jayantha Gunaratne,Olav Engebraaten,Olav Engebraaten,James L. Manley,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Paul M. Neilsen,Carol Prives +22 more
TL;DR: It is surmised that mutant p53 impacts transcription of VEGFR2 as well as myriad other genes by promoter remodeling through interaction with and likely regulation of the SWI/SNF chromatin remodeling complex, which means that not only might mutants p53-expressing tumors be susceptible to anti VEGF therapies, impacting SWI-SNF tumor suppressor function in mutant p 53 tumors may also have therapeutic potential.
Journal ArticleDOI
The p53 C Terminus Controls Site-Specific DNA Binding and Promotes Structural Changes within the Central DNA Binding Domain
Oleg Laptenko,Idit Shiff,William A. Freed-Pastor,Andrew Zupnick,Melissa Mattia,Ella Freulich,Inbal Shamir,Noam Kadouri,Tamar Kahan,James J. Manfredi,Itamar Simon,Carol Prives +11 more
TL;DR: The results provide several unanticipated and interconnected findings that enable stable formation of p53-DNA complexes to divergent binding sites via DNA-induced conformational changes within the DBD itself.